Eric K. Rowinsky Joins ADVENTRX Board of Directors
February 25 2008 - 6:00AM
PR Newswire (US)
SAN DIEGO, Feb. 25 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that Eric K.
Rowinsky, M.D., Chief Medical Officer and Executive Vice President
of ImClone Systems Incorporated, will join its Board of Directors.
In connection with Dr. Rowinsky's appointment, ADVENTRX increased
the size of its Board from six to seven directors. "We are
delighted to welcome Eric to our Board of Directors. He brings
tremendous knowledge and expertise within the oncology field,"
stated Evan M. Levine, ADVENTRX's Chief Executive Officer and
President. "We believe his experience will be an important asset as
we advance our product candidates through the clinic," added Mr.
Levine. "I'm very pleased to be joining ADVENTRX's Board of
Directors," commented Dr. Rowinsky. "I hope my contributions help
advance the development and commercialization of the Company's
product candidates, which hold significant potential to provide
patients with better treatment options." Prior to joining ImClone
Systems in 2005, Dr. Rowinsky focused his academic efforts in
cancer drug development as the Director of Clinical Research and
later Director of the Institute for Drug Development of the Cancer
Therapy and Research Center in San Antonio and the SBC Endowed
Chair for Early Drug Development from 1996 to 2005. He was also
Clinical Professor of Medicine in the Division of Medical Oncology
at the University of Texas Health Science Center at San Antonio
from 1996 to 2006. From 1987 to 1996, Dr. Rowinsky served as an
Associate Professor of Oncology at the Johns Hopkins University
School of Medicine. He was a longstanding NCI principal
investigator on U01 anticancer drug development grants and
integrally involved in pivotal clinical and preclinical
investigations which led to the development of paclitaxel,
docetaxel, topotecan, irinotecan, erlotinib and gefitinib, among
others. Dr. Rowinsky is the Editor-in-Chief of Investigational New
Drugs, an Associate Editor and/or Editorial Board Member of Cancer
Research (Associate Editor and Reviews Editor), Clinical Cancer
Research, Annals of Oncology, Cancer Biology and Therapy and
several other oncology journals and has published over 270
manuscripts in both the preclinical and clinical research fields.
He has also served on the Scientific Advisory Board and Project
Advisory Boards of a large number of pharmaceutical and
biotechnology companies and has advised and/or presented aspects of
New Drug Applications to the FDA on several occasions. Dr.
Rowinsky's honors include receipt of the career development award
of the American Cancer Society and the 6th Annual Emil J. Freireich
Award for outstanding achievement of a young researcher in clinical
cancer therapeutics. He also served on the Board of Scientific
Counselors of the National Cancer Institute. Dr. Rowinsky received
his B.A. degree from New York University and his M.D. from the
Vanderbilt University School of Medicine. Following his residency
in internal medicine at the University of California, he completed
fellowship training in medical oncology at the Johns Hopkins
University School of Medicine. About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The
Company seeks to improve the performance and safety of existing
treatments by addressing significant problems such as drug
metabolism, bioavailability, excessive toxicity and treatment
resistance. More information can be found on the Company's web site
at http://www.adventrx.com/. Forward Looking Statements ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they
materialize or do not prove to be accurate, could cause ADVENTRX's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: the risk
that ADVENTRX will be unable to raise sufficient capital to fund
the projects necessary to meet its anticipated or stated goals and
milestones; the risk that preclinical results are not indicative of
the success of subsequent clinical trials and the results of
pending clinical trials; the potential for ADVENTRX's product
candidates to receive regulatory approval for one or more
indications on a timely basis or at all, and the uncertain process
of seeking regulatory approval; other difficulties or delays in
manufacturing, marketing and obtaining regulatory approval for
ADVENTRX's product candidates; the potential for regulatory
authorities to require additional preclinical work or other
clinical requirements to support regulatory filings; the market
potential for ADVENTRX's product candidates and ADVENTRX's ability
to compete in those markets; the scope and validity of patent
protection for ADVENTRX's product candidates; patent and non-patent
exclusivity covering Navelbine(R) and Taxotere(R); and other risks
and uncertainties more fully described in ADVENTRX's press releases
and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at http://www.sec.gov/. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend
to update any forward-looking statement as set forth in this press
release to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals,
Inc., +1-858-552-0866 Web site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024